Jazz Patent Suit Over Xyrem Survives Dismissal In NJ
A New Jersey federal judge has refused to let generic-drug company Tris Pharma Inc. escape a suit claiming its attempt to sell a competing version of Jazz Pharmaceuticals' narcolepsy drug Xyrem...To view the full article, register now.
Already a subscriber? Click here to view full article